Globo-series Gb4 activates ERK and promotes the proliferation of osteoblasts.

Globoside (Gb4) Glycosphingolipids Osteoblasts

Journal

Journal of oral biosciences
ISSN: 1880-3865
Titre abrégé: J Oral Biosci
Pays: Netherlands
ID NLM: 101226721

Informations de publication

Date de publication:
06 Nov 2023
Historique:
received: 30 10 2023
revised: 30 10 2023
accepted: 30 10 2023
medline: 9 11 2023
pubmed: 9 11 2023
entrez: 8 11 2023
Statut: aheadofprint

Résumé

Globo-series Gb4 (globoside) is involved in the immune system and disease pathogenesis. We recently reported that systemic Gb4 deficiency in mice led to decreased bone formation due to a reduction in osteoblast number. However, it remains unclear whether Gb4 expressed in osteoblasts promotes their proliferation. Therefore, we investigated the role of Gb4 in osteoblast proliferation in vitro. We examined osteoblast proliferation in Gb3 synthase knockout mice lacking Gb4. We investigated the effects of Gb4 synthase knockdown in the mouse osteoblast cell line MC3T3-E1 on its proliferation. Furthermore, we administered Gb4 to MC3T3-E1 cells in which Gb4 was suppressed by a glucosylceramide synthase (GCS) inhibitor and evaluated its effects on their proliferation. To elucidate the mechanisms by which Gb4 promotes osteoblast proliferation, the phosphorylated extracellular signal-regulated kinases 1 and 2 (ERK1/2) levels were measured in MC3T3-E1 cells. Osteoblast proliferation was lower in Gb3 synthase knockout mice lacking Gb4 than in wild-type mice. Proliferation was inhibited by Gb4 synthase knockdown in MC3T3-E1 cells. Furthermore, the administration of Gb4 to MC3T3-E1 cells, in which a GCS inhibitor suppressed Gb4, promoted their proliferation. Moreover, it increased the phosphorylated ERK1/2 levels in MC3T3-E1 cells. Our results suggest that Gb4 expressed in osteoblasts promotes their proliferation through ERK1/2 activation.

Identifiants

pubmed: 37939880
pii: S1349-0079(23)00179-2
doi: 10.1016/j.job.2023.10.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors are required to disclose any COI within the period of 12 months prior to the submission of any manuscript in the subject matter of which any company, entity, or organization has an interest.

Auteurs

Hanami Kato (H)

Department of Pharmacology, School of Dentistry, Aichi Gakuin University, Nagoya, Japan; Department of Orthodontics, School of Dentistry, Aichi Gakuin University, Nagoya, Japan.

Mayu Nagao (M)

Department of Pharmacology, School of Dentistry, Aichi Gakuin University, Nagoya, Japan.

Koichi Furukawa (K)

Department of Biomedical Sciences, Chubu University College of Life and Health Sciences, Kasugai, Aichi, Japan.

Yoshitaka Mishima (Y)

Department of Pharmacology, School of Dentistry, Aichi Gakuin University, Nagoya, Japan.

Shota Ichikawa (S)

Department of Pharmacology, School of Dentistry, Aichi Gakuin University, Nagoya, Japan; Department of Orthodontics, School of Dentistry, Aichi Gakuin University, Nagoya, Japan.

Takuma Sato (T)

Department of Orthodontics, School of Dentistry, Aichi Gakuin University, Nagoya, Japan.

Ken Miyazawa (K)

Department of Orthodontics, School of Dentistry, Aichi Gakuin University, Nagoya, Japan.

Kazunori Hamamura (K)

Department of Pharmacology, School of Dentistry, Aichi Gakuin University, Nagoya, Japan. Electronic address: hamak@dpc.agu.ac.jp.

Classifications MeSH